Patients with CAD are commonly recommended treatment with ACE inhibitors10, which have been proven to reduce serum ACE levels11 and thereby mimic the ACE phenotype categorised by the ACE I/I homozygotes. The gene discussed is ACE; the disease is coronary artery disorder.